102735-88-6

Basic information

• Product Name: 4-FLUORO-2,6-DINITROTOLUENE
• Synonyms: 4-FLUORO-2,6-DINITROTOLUENE;Benzene, 5-fluoro-2-Methyl-1,3-dinitro-;5-Fluoro-2-Methyl-1,3-dinitro-benzene;2,6-dinitro-4-fluoro-tolurene
• CAS NO: 102735-88-6
• Molecular Formula: C₇H₅FN₂O₄
• Molecular Weight: 200.12
• Mol File: 102735-88-6.mol

Chemical Properties

• Boiling Point: 282.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.497±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-FLUORO-2,6-DINITROTOLUENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-2,6-DINITROTOLUENE(102735-88-6)
• EPA Substance Registry System: 4-FLUORO-2,6-DINITROTOLUENE(102735-88-6)

Safety Data

• Hazardous Substances Data: 102735-88-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-FLUORO-2,6-DINITROTOLUENE is used as a key intermediate in the synthesis of quinazolinone derivatives, which are known as TNF-α inhibitors. These inhibitors are valuable for the treatment of cancer and inflammation, as they help regulate the immune response and reduce inflammation.
Used in Chemical Synthesis:
4-FLUORO-2,6-DINITROTOLUENE is also used as a building block in the synthesis of various organic compounds, including dyes, agrochemicals, and other specialty chemicals. Its unique structure allows for further functionalization and modification, making it a useful component in the development of new materials and products.

Upstream product

• 446-10-6 2-nitro-4-fluorotoluene 
• 352-32-9 p-fluorotoluene 

Downstream Products

• 168770-44-3 5-fluoro-2-methyl-3-nitroaniline 
• 168770-45-4 7-amino-5-fluoro-8-methylquinoline 
• 885520-14-9 6-fluoro-4-nitro-1H-indazole 
• 1167055-65-3 C₈H₈FNO₃ 
• 1058142-18-9 ethyl 6-fluoro-4[(phenoxycarbonyl)amino]-1H-indazole-1-carboxylate 
• 1389326-41-3 3-(4-amino-6-fluoro-1H-indol-1-yl)-3-(4-chlorophenyl)-2-methylpentan-2-ol 
• 1389326-40-2 tert-butyl 1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-6-fluoro-1H-indol-4-ylcarbamate 
• 1389324-99-5 N-(1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-6-fluoro-1H-indol-4-yl)methanesulfonamide 
• 1389326-39-9 methyl 2-(4-chlorophenyl)-2-(6-fluoro-4-(methylsulfonamido)-1H-indol-1-yl)butanoate 
• 1389326-37-7 methyl 2-(4-amino-6-fluoro-1H-indol-1-yl)-2-(4-chlorophenyl)butanoate 
• 1389326-36-6 methyl 2-(4-(tert-butoxycarbonylamino)-6-fluoro-1H-indol-1-yl)-2-(4-chlorophenyl)butanoate 
• 1389326-35-5 methyl 2-(4-(tert-butoxycarbonylamino)-6-fluoro-1H-indol-1-yl)-2-(4-chlorophenyl)acetate 
• 1389326-34-4 methyl 2-(4-amino-6-fluoro-1H-indol-1-yl)-2-(4-chlorophenyl)acetate 
• 1389326-33-3 2-(4-(tert-butoxycarbonylamino)-6-fluoro-1H-indol-1-yl)-2-(4-chlorophenyl)acetic acid 

Relevant articles and documents

QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS

Disclosed are a quinazolinone derivative, a preparation method therefor, a pharmaceutical composition, and applications. Provided are a compound represented by formula I, a pharmaceutically acceptable salt, a solvate, a crystal form, a eutectic crystal, a

Indazole compounds and application thereof to preparation of IDO inhibitors

The invention discloses indazole compounds as shown in a formula (i) or (II) which is described in the specification, and a preparation method thereof, and application of the compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections related to cellular immune activation,autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

Indazole compounds containing nitrogen substituents, and application of same as IDO inhibitors

The invention discloses nitrogen substituent-containing indazole compounds as shown in a formula (I) which is described in the specification, a preparation method for the compounds, and application ofthe compounds as IDO inhibitors. The compounds provided by the invention can be used for preventing and/or treating a plurality of diseases, such as Alzheimer's disease, cataract, infections relatedto cellular immune activation, autoimmune diseases, AIDS, cancers, depression, the metabolic disorder of tryptophan or the like.

MINERALOCORTICOID RECEPTOR ANTAGONISTS

The present invention is directed to compounds of the Formula I: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiome

MINERALOCORTICOID RECEPTOR ANTAGONISTS

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophyl

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

Substituted 2-nitrobenzyltrichloroacetate esters for photodirected oligonucleotide detritylation in solid films

Oligonucleotide microarray fabrication by chemical synthesis using photoacid generators in solid films could have advantages over existing methods, but has not matched the accuracy of conventional synthesis where detritylation is performed with acid solut

INDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

The present invention relates to indazole derivatives of the following formula I, which can be used as vanilloid receptor ligands, processes for their preparation, and their use in treating diseases, conditions and/or disorders modulated by vanilloid receptors. (I)

7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS

This invention involves involves the use of compounds having the following structure: STR1 wherein: (a) R is unsubstituted C 1-C. sub.3 alkanyl or alkenyl; and(b) R' is selected from hydrogen; unsubstituted C 1-C 3 alkanyl or alkenyl; unsubstituted

7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2-ADRENOCEPTOR AGONISTS

The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: STR1 wherein: (a) R is unsubst